6370 Nancy Ridge Drive
Suite 106
Welcome to Scrip
Create an account to read this article
Already a subscriber?
Polaris Group
Polaris Group's Phase II candidate is a microbial enzyme that degrades arginine, an amino acid crucial to tumor cell metabolism and growth. Depleting arginine from the blood can control tumor growth, but normal cells retain their ability to synthesize arginine so should not be harmed by the enzyme's effects.
More from Archive
• By
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
• By
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.
• By
CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.
• By
A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand
More from Scrip
• By
The FDA go-ahead makes it the first for a BTK inhibitor in immune thrombocytopenia. Sanofi hopes it will mark the start of a number of indications for rilzabrutinib.
• By
Alnylam and Roche refine zilebesiran’s Phase III trial design after a Phase II miss, focusing on patients on diuretics.
• By
In this week's episode: Lilly’s orforglipron strong in diabetic obesity; Ascletis confident in oral GLP-1 challenger; myostatin drugs progress for obesity; an interview with OneSource’s CEO; and an analysis of Dupixent’s pipeline-in-a-product success.